Zealand Pharma

Update in progress

ZEAL.CO (Copenhagen)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Zealand Pharma A/S is a biotechnology company focused on discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. Its portfolio targets gastrointestinal and metabolic diseases and other unmet medical needs. It develops Zegalogue for severe hypoglycemia and Dasiglucagon bi-hormone artificial pancreas systems. It is advancing glepaglutide (GLP-2 analog) in Phase III for short bowel syndrome. Founded in 1997, based in Søborg, Denmark.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive